Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIX NASDAQ:AURA NASDAQ:CGEM NASDAQ:FULC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.52+20.1%$3.10$2.07▼$4.20$96.61M0.5861,894 shs579,631 shsAURAAura Biosciences$5.97-3.4%$6.63$4.34▼$12.38$383.90M0.45151,692 shs164,287 shsCGEMCullinan Therapeutics$6.35-2.8%$7.57$6.32▼$18.62$385.76M-0.08527,741 shs568,631 shsFULCFulcrum Therapeutics$7.07+1.0%$7.08$2.32▼$8.50$378.64M2.82381,938 shs424,365 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences+20.14%+18.12%+18.52%-4.35%+5.07%AURAAura Biosciences-3.40%-7.73%-11.16%-3.40%-40.71%CGEMCullinan Therapeutics-2.76%-7.16%-17.10%-23.68%-64.62%FULCFulcrum Therapeutics+1.00%-2.75%+3.67%+9.95%+122.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.52+20.1%$3.10$2.07▼$4.20$96.61M0.5861,894 shs579,631 shsAURAAura Biosciences$5.97-3.4%$6.63$4.34▼$12.38$383.90M0.45151,692 shs164,287 shsCGEMCullinan Therapeutics$6.35-2.8%$7.57$6.32▼$18.62$385.76M-0.08527,741 shs568,631 shsFULCFulcrum Therapeutics$7.07+1.0%$7.08$2.32▼$8.50$378.64M2.82381,938 shs424,365 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences+20.14%+18.12%+18.52%-4.35%+5.07%AURAAura Biosciences-3.40%-7.73%-11.16%-3.40%-40.71%CGEMCullinan Therapeutics-2.76%-7.16%-17.10%-23.68%-64.62%FULCFulcrum Therapeutics+1.00%-2.75%+3.67%+9.95%+122.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 3.00Buy$9.00155.68% UpsideAURAAura Biosciences 3.00Buy$22.00268.51% UpsideCGEMCullinan Therapeutics 3.00Buy$27.67335.70% UpsideFULCFulcrum Therapeutics 3.00Buy$9.6035.79% UpsideCurrent Analyst Ratings BreakdownLatest ANIX, CGEM, AURA, and FULC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025CGEMCullinan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.009/11/2025ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.009/10/2025CGEMCullinan TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.009/9/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/21/2025CGEMCullinan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$24.008/19/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/19/2025AURAAura BiosciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/18/2025CGEMCullinan TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$35.00 ➝ $28.008/13/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.008/5/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.007/30/2025FULCFulcrum TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$4.00 ➝ $5.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K551.80N/AN/A$0.59 per share5.97AURAAura BiosciencesN/AN/AN/AN/A$3.04 per shareN/ACGEMCullinan TherapeuticsN/AN/AN/AN/A$10.14 per shareN/AFULCFulcrum Therapeutics$80M4.78N/AN/A$4.51 per share1.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$12.55M-$0.35N/A∞N/AN/A-67.45%-59.18%N/AAURAAura Biosciences-$86.92M-$1.96N/AN/AN/AN/A-64.44%-54.24%11/11/2025 (Estimated)CGEMCullinan Therapeutics-$167.38M-$3.23N/AN/AN/AN/A-36.56%-34.82%11/6/2025 (Estimated)FULCFulcrum Therapeutics-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%11/12/2025 (Estimated)Latest ANIX, CGEM, AURA, and FULC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/10/2025Q3 2025ANIXAnixa Biosciences-$0.10-$0.07+$0.03-$0.07N/AN/A8/13/2025Q2 2025AURAAura Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A8/7/2025Q2 2025CGEMCullinan Therapeutics-$0.83-$1.07-$0.24-$1.07N/AN/A7/29/2025Q2 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AAURAAura BiosciencesN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A8.458.45AURAAura BiosciencesN/A12.3912.39CGEMCullinan TherapeuticsN/A9.839.83FULCFulcrum TherapeuticsN/A24.4224.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%AURAAura Biosciences96.75%CGEMCullinan Therapeutics86.31%FULCFulcrum Therapeutics89.83%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences25.30%AURAAura Biosciences6.30%CGEMCullinan Therapeutics6.07%FULCFulcrum Therapeutics7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences532.92 million24.59 millionOptionableAURAAura Biosciences5062.12 million58.21 millionNot OptionableCGEMCullinan Therapeutics3059.07 million55.49 millionOptionableFULCFulcrum Therapeutics10054.09 million50.31 millionOptionableANIX, CGEM, AURA, and FULC HeadlinesRecent News About These Companies147,654 Shares in Fulcrum Therapeutics, Inc. $FULC Acquired by Jacobs Levy Equity Management Inc.September 15 at 3:19 AM | marketbeat.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 12, 2025 | globenewswire.comExome Asset Management LLC Purchases 405,538 Shares of Fulcrum Therapeutics, Inc. $FULCSeptember 11, 2025 | marketbeat.comInvesco Ltd. Raises Stake in Fulcrum Therapeutics, Inc. $FULCSeptember 9, 2025 | marketbeat.comNuveen LLC Makes New $441,000 Investment in Fulcrum Therapeutics, Inc. $FULCSeptember 7, 2025 | marketbeat.comADAR1 Capital Management LLC Raises Stake in Fulcrum Therapeutics, Inc. $FULCSeptember 4, 2025 | marketbeat.comFulcrum Therapeutics, Inc. $FULC Shares Bought by Nantahala Capital Management LLCSeptember 3, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Lowers Position in Fulcrum Therapeutics, Inc. $FULCSeptember 3, 2025 | marketbeat.comMaxion Therapeutics Strengthens Board with Appointment of Dr. Santiago Arroyo as a Non-Executive DirectorAugust 27, 2025 | markets.businessinsider.comFulcrum Therapeutics to Present at Upcoming Investor Conferences in September 2025August 26, 2025 | quiverquant.comQFulcrum Therapeutics to Present at Upcoming Investor MeetingsAugust 26, 2025 | globenewswire.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 24, 2025 | marketbeat.comFulcrum Therapeutics, Inc. $FULC Shares Sold by Connor Clark & Lunn Investment Management Ltd.August 20, 2025 | marketbeat.comThree Key Reasons Why Securities Class Actions Are Failing on Material Misrepresentation Grounds in the District of MassachusettsAugust 14, 2025 | jdsupra.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 8, 2025 | globenewswire.comAIRNA Appoints Tamara Joseph as Chief Legal Officer and Kristina Storey as Head of Regulatory AffairsAugust 6, 2025 | finance.yahoo.comFULC Fulcrum Therapeutics, Inc. - Seeking AlphaAugust 5, 2025 | seekingalpha.comFulcrum Therapeutics upgraded to Buy from Neutral at H.C. WainwrightJuly 30, 2025 | msn.comFulcrum Therapeutics shares slide 17% after sickle cell trial resultsJuly 29, 2025 | msn.comFulcrum reports data from sickle cell disease trial, posts Q2 resultsJuly 29, 2025 | msn.comFulcrum Therapeutics stock falls after sickle cell disease trial resultsJuly 29, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 20253 Under-the-Radar Biotechs Under $5 That Could Soar 200%By Chris Markoch | September 9, 2025ANIX, CGEM, AURA, and FULC Company DescriptionsAnixa Biosciences NASDAQ:ANIX$3.52 +0.59 (+20.14%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$3.56 +0.04 (+1.16%) As of 09/15/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Aura Biosciences NASDAQ:AURA$5.97 -0.21 (-3.40%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$5.95 -0.02 (-0.32%) As of 09/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Cullinan Therapeutics NASDAQ:CGEM$6.35 -0.18 (-2.76%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$6.36 +0.01 (+0.16%) As of 09/15/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Fulcrum Therapeutics NASDAQ:FULC$7.07 +0.07 (+1.00%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$7.07 0.00 (0.00%) As of 09/15/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
